Major Controversies
Herbalife Short Position
In December 2012, Bill Ackman, through his hedge fund Pershing Square Capital Management, disclosed a $1 billion short position against Herbalife Ltd., publicly alleging that the multi-level marketing company operated as a pyramid scheme reliant on distributor recruitment rather than genuine product sales.[47] Ackman argued that over 90% of distributors lost money, with evidence drawn from internal company data and distributor testimonies suggesting unsustainable economics where earnings claims exaggerated retail sales potential.[48] He initiated a high-profile campaign, including a three-hour presentation to investors and regulators, lobbying efforts targeting the Federal Trade Commission (FTC), and funding the 2016 documentary Betting on Zero, which amplified claims of fraudulent practices.[49]
The position drew fierce opposition from investors like Carl Icahn, who in early 2013 publicly challenged Ackman on CNBC, acquiring a significant long stake in Herbalife and betting against Ackman's short, escalating into a personal feud that highlighted divisions in activist investing circles.[50] Herbalife defended its model as legitimate direct selling, with retail product sales to end consumers forming the core, and countersued Ackman for market manipulation, though courts dismissed related claims against him.[51] Ackman's campaign cost Pershing Square tens of millions in public relations and legal expenses, while the short position incurred mounting mark-to-market losses as Herbalife shares rose, reaching an estimated $400-500 million by late 2013.[47][52]
In July 2016, the FTC announced a settlement with Herbalife requiring a $200 million consumer redress payment and structural changes, including mandates that at least 80% of sales in the U.S. occur to non-distributors and verifiable tracking of retail transactions to curb deceptive earnings representations.[53] The agency cited misleading income claims but did not classify the company as a pyramid scheme or order its dissolution, prompting Ackman to describe it as a "significant win" for exposing flaws, though critics noted the agreement allowed operations to continue with reforms rather than validating his full allegations.[54][55] Herbalife shares surged nearly 20% immediately post-announcement, exacerbating Ackman's unrealized losses.[56]
Facing persistent stock gains—Herbalife shares climbed over 50% in 2017—Ackman capped losses in November 2017 by closing the direct short and shifting to put options, fully exiting the position by early 2018 with total losses estimated at approximately $760 million against his initial billion-dollar bet.[57][58] The breakeven price for the trade hovered around $48 per share, while Herbalife closed above $92 upon exit, underscoring the financial toll amid unproven claims of imminent collapse.[59] Subsequent developments, such as Herbalife's 2022 $12.5 million settlement of unrelated RICO allegations without admitting wrongdoing, have not reversed the trade's outcome, though Ackman later referenced a "psychological short" in 2024 amid stock declines.[60][61] The saga exemplified risks in high-conviction shorts against resilient businesses, influencing Ackman's subsequent shift toward concentrated long positions.
Valeant Pharmaceuticals Campaign
In 2014, Pershing Square Capital Management, led by Bill Ackman, began evaluating Valeant Pharmaceuticals' acquisition-driven business model, which emphasized buying established drugs, slashing research and development costs, and boosting revenues through price increases and distribution via specialty pharmacies.[62] By early 2015, the fund had built an initial stake valued at approximately $3 billion, representing about 5% of Valeant's shares, with Ackman publicly praising the company's efficiency in contrast to traditional pharmaceutical firms burdened by high R&D spending.[63] Ackman positioned Valeant as a superior alternative, arguing its model generated higher returns for shareholders by focusing on marketing and pricing optimization rather than innovation pipelines that often yielded low success rates.[31]
Ackman's activist campaign intensified in 2015 as Pershing Square increased its holding to nearly 10% by November, making it Valeant's largest shareholder; he joined the board alongside Vice Chairman Stephen Fraidin to influence strategy.[64] [65] The stake's value peaked amid a stock surge to around $260 per share in summer 2015, but scrutiny mounted over Valeant's reliance on Philidor Rx Services, a mail-order pharmacy accounting for up to 7% of revenues, amid allegations of channel stuffing—shipping excess inventory to artificially inflate sales.[66] [67] In October 2015, Valeant severed ties with Philidor following reports of improper practices, including potential fraud, which triggered a congressional probe into drug pricing and a sharp stock decline of over 70% from its highs.[68] [69]
Ackman mounted a vigorous defense, hosting a four-hour conference call on October 30, 2015, to assert that Valeant's issues stemmed primarily from public relations failures and media exaggeration rather than systemic fraud, while downplaying Philidor's role and projecting recovery through operational fixes.[70] [71] He urged patience from investors, emphasizing long-term value and even acquiring additional shares in February 2016 amid the turmoil, bringing holdings to over 30 million shares including options.[72] Internal emails later revealed Ackman's private frustrations with Valeant's leadership, including suggestions for countering critics and concerns over reputational damage, though he publicly maintained optimism.[73] [74] The campaign faltered as ongoing revelations of accounting irregularities and debt burdens—Valeant's leverage exceeded $30 billion—led to CEO J. Michael Pearson's resignation in April 2016; Ackman testified before Congress on pricing but could not stem the stock's collapse to under $10 per share.[75] [76]
By March 2017, Pershing Square fully exited its Valeant position, realizing losses estimated at $3 billion to over $4 billion from an average purchase price near $190 per share, which contributed to the fund's dismal performance: -20.5% in 2015 and -13.5% in 2016, prompting investor redemptions and a strategic pivot away from concentrated bets.[77] [66] [78] Ackman later reflected on the episode as a humbling lesson in risk management, acknowledging deviations from his typical investment principles, such as Valeant's limited emphasis on organic growth, while defending the underlying thesis against what he viewed as overblown short-seller attacks.[79] [80] The Valeant saga damaged Ackman's reputation temporarily but did not end his career, as he shifted toward more diversified, lower-risk strategies at Pershing Square.[81]
COVID-19 Response and Market Bets
In February 2020, anticipating severe economic fallout from the emerging COVID-19 pandemic, Bill Ackman directed Pershing Square Capital Management to purchase around $27 million in credit protection, primarily through credit default swaps on 300 million euros of high-yield European corporate bonds and similar instruments on U.S. investment-grade debt.[82][83] These hedges, initiated after Ackman's personal alarm over the virus's spread following a nightmare and analysis of Italian cases, expanded dramatically as global markets plunged in March amid lockdowns and uncertainty, generating $2.6 billion in profits by March 23, when Pershing Square fully exited the positions.[84][85] Ackman then pivoted aggressively to long equity bets, deploying the proceeds into undervalued stocks including Hilton Worldwide Holdings and Howard Hughes Corporation, which contributed to the fund's broader pandemic-related gains approaching $4 billion by early 2022.[86][87]
Ackman's public response emphasized urgency, including a March 18, 2020, CNBC interview where he warned of an impending "tsunami" of economic destruction—stating "hell is coming"—and urged President Trump to impose a mandatory 30-day nationwide shutdown, coupled with a government-backed "rent, interest, and tax holiday" to avert deeper collapse while containing the virus.[88][89] The appearance preceded a 7% market circuit breaker halt that day, prompting accusations from some market participants that his rhetoric fueled panic selling, though Ackman countered that it aimed to catalyze policy action and that he viewed the lockdown as a pathway to rapid recovery, having entered personal lockdown weeks earlier.[90][91] To support containment, he allocated personal funds to Covaxx, a firm developing antibody testing kits for faster detection beyond PCR methods.[92]
Over time, Ackman's stance evolved amid ongoing policy debates; in January 2021, he decried delays in vaccinating high-risk elderly populations as "genocide," pressing for prioritization based on efficacy data showing strong protection against severe outcomes.[93] By mid-2023, however, he criticized the government's handling of COVID-19 measures, including vaccines, for insufficient scrutiny of skeptics' concerns over safety and long-term effects, amplifying Robert F. Kennedy Jr.'s arguments and pledging $150,000 toward a proposed debate between vaccine critics and proponents like Anthony Fauci to foster transparency.[94][95] He clarified his position as pro-vaccination for at-risk groups but advocated open discourse on mandates and boosters, citing empirical questions about transmission prevention and rare adverse events from pharmacovigilance data.[96]
University Scandals and DEI Criticisms
In the aftermath of the October 7, 2023, Hamas attack on Israel, which killed approximately 1,200 people and took over 250 hostages, student groups at Harvard University and other elite institutions issued statements attributing responsibility to Israel rather than unequivocally condemning the violence. Bill Ackman, a Harvard alumnus and major donor, publicly demanded that Harvard identify and release the names of students involved in these statements, arguing that such actions reflected antisemitic views and that universities failed to protect Jewish students from harassment.[97][98] He also urged corporate donors and alumni to withhold financial contributions until universities addressed the surge in antisemitic incidents, including threats and exclusion of Jewish students from campus events.[97] On November 6, 2023, Ackman published a 3,138-word open letter to Harvard President Claudine Gay, criticizing the university's inadequate response, such as Gay's speech on antisemitism delivered only to Jewish audiences at a Hillel event, and calling for mandatory viewpoint diversity training and the resignation of complicit administrators.[99][100]
Ackman's criticisms intensified following the December 5, 2023, congressional hearing where Gay, along with University of Pennsylvania President Liz Magill and MIT President Sally Kornbluth, testified before the House Education and Workforce Committee on campus antisemitism. When questioned by Representative Elise Stefanik whether calls for the "genocide of Jews" would violate university policies, the presidents gave conditional responses emphasizing context, which Ackman described as morally bankrupt and evasive, arguing it enabled harassment by failing to classify such rhetoric as violations.[101][102] He demanded the immediate resignations of all three presidents, stating they had disqualified themselves from leadership. Magill resigned on December 9, 2023; Gay stepped down on January 2, 2024, after six months in office—the shortest tenure of any Harvard president—amid scrutiny over her handling of antisemitism and subsequent allegations of plagiarism in her scholarly work, which Ackman amplified by hiring investigators to review her publications.[103][104] Following Gay's exit, Ackman called for the resignation of Harvard's governing board, including Chair Penny Pritzker, accusing them of prioritizing ideological loyalty over merit.[105]
Ackman linked these scandals to broader failures in university governance, particularly diversity, equity, and inclusion (DEI) initiatives, which he characterized as inherently discriminatory and antithetical to meritocracy. In a January 3, 2024, 4,000-word post on X (formerly Twitter), he argued that DEI programs promote a zero-sum "oppressor-oppressed" worldview, categorizing Jews and Israelis as oppressors, which he claimed fueled antisemitic campus climates by subordinating individual rights to group identities and seeking equality of outcome rather than opportunity.[106][107] He contended that DEI undermines capitalism and free markets by rejecting competence-based advancement, citing examples like the prioritization of racial quotas in admissions and hiring that disadvantage high-achieving Asian and white applicants.[107] Ackman further blamed DEI ideologies for the scale of pro-Palestinian protests in spring 2024, asserting they indoctrinate students to view Western institutions, including Israel, as systemic oppressors, and urged businesses to avoid hiring graduates from campuses tolerant of such views.[108] His stance drew counteraccusations of hypocrisy when his wife, Neri Oxman, faced plagiarism claims in her MIT dissertation shortly after Ackman's campaign against Gay, though Ackman defended her work as properly cited.[109] Despite pushback from academia and media outlets framing his efforts as bullying, Ackman maintained that elite universities' left-leaning biases had eroded standards, evidenced by Gay's appointment despite limited publications and the board's initial defense of her amid evidence of unattributed text in at least four papers.[110][104]